Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21793953 | 0.92 | FUCA1 (0.56) | FUCA1SIGMAR1ACHECYP2D6CCR3 | |
| SCHEMBL21793950 | 0.92 | FUCA1 (0.56) | FUCA1SIGMAR1ACHECYP2D6CCR3 | |
| SCHEMBL5750271 | 0.92 | FUCA1 (0.56) | FUCA1SIGMAR1ACHECYP2D6CCR3 | |
| SCHEMBL20488466 | 0.87 | FUCA1 (0.60) | FUCA1SIGMAR1ACHECYP2D6CYP1A2 | |
| SCHEMBL2955795 | 0.87 | FUCA1 (0.60) | FUCA1SIGMAR1ACHECYP2D6CYP1A2 | |
| SCHEMBL6201856 | 0.87 | FUCA1 (0.51) | FUCA1SIGMAR1ACHECYP2D6CCR3 | |
| Hydrochloric Acid SCHEMBL20488123 | 0.85 | FUCA1 (0.58) | FUCA1SIGMAR1ACHEALDH1A1S1PR1 | |
| SCHEMBL10480210 | 0.85 | OPRM1 (0.48) | FUCA1SIGMAR1ACHECYP2D6 | |
| SCHEMBL6202706 | 0.83 | ACHE (0.56) | FUCA1SIGMAR1ACHECYP2D6CCR3 | |
| SCHEMBL11413096 | 0.83 | FUCA1 (0.60) | FUCA1SIGMAR1ACHECYP2D6CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397365-B1 | HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH AS (DK) | 2005-02-16 | — | — | EP | disclosed |
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | disclosed |
| EP-1397365-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NeuroSearch A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096911-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH A/S (DK) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | CHRNA3, CHRNA5, CHRNA2 | FUCA1 892/4885SIGMAR1 92/4885ACHE 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.